What Could IPO and M&A Markets Look Like in the Coming Quarter?

What could the acquisition of TearScience and Kala Pharmaceuticals mean for the broader M&A and IPO activity? We ask Andrew Gitkin, managing director and head of West Coast biotechnology investment banking at Piper Jaffray.

STAY UP TO DATE WITH OIS

Get the Latest News, Podcasts and Videos.